Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer

Renal Cancers Clinical Trial

Official title:

A Phase II Trial of Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Primary Renal Cancer (RCC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02141919
• Other study ID #: STU 122013-030
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 2013
• Est. completion date: December 2025

Study information

• Verified date: August 2023
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this phase II clinical trial is to evaluate the efficacy of the completely non-invasive treatment option of stereotactic radiation therapy for the treatment of biopsy proven and growing small renal tumors.

Description:

Current treatment options for primary renal cancer include surgery or ablative techniques-all are invasive or minimally invasive options. The completely noninvasive treatment option of stereotactic radiation therapy (SABR), which has become standard of care in many cancer sites, has not been explored for primary renal cancer. With multiple technological advances, it is now feasible to safely treat a moving intra-abdominal tumor such as that in a kidney. This proposed clinical trial evaluates the efficacy of SABR in treating patients with early renal cancers. Growing renal masses will first be biopsied to confirm the diagnosis of renal cancer. Patients will then undergo treatment with SABR of 3-5 fractions completing within three weeks. Treatment response will be evaluated using sequential MRI scans and a second tumor biopsy one year after treatment. Monitoring of treatment toxicity and kidney function will also be performed.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 16
• Est. completion date: December 2025
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria

• Age = 18 years.

• Renal mass = 5cm

• The treating renal mass must be = 5cm. Other renal masses (cysts etc.) of any size will not make the subject ineligible

• Biopsy proven Renal neoplasm

• All histology of renal cancers are included including oncocytoma

• Growth of renal mass >2mm in radiographic scans must be demonstrated within a one year period.

• Ability to understand and the willingness to sign a written informed consent.

• Subject is able to undergo either an MRI or administration of contrast agent for CT

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

• A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

• Has not undergone a hysterectomy or bilateral oophorectomy; or

• Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

Exclusion Criteria:

• Subject has received any treatment for the treating renal mass; such as RFA or cyroablation.

• If other renal masses received RFA or cryoablation or surgery, then these patients are eligible.

• Subjects received previous abdominal radiation

• Evidence of Metastatic Disease, unless disease-free for = 3 years prior to registration, (non-melanomatous skin cancer and in-situ cancers are okay).

• Female subjects who are pregnant or planning to become pregnant during the course of SABR.

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Kidney Neoplasms
• Renal Cancers

Intervention

Radiation:
• Stereotactic Ablative Radiation Therapy
Stereotactic Ablative Body Radiation Therapy (SABR): 3 fractions of 12Gy, or 4 fractions of 10Gy or 5 fractions of 8 Gy

Locations

Country	Name	City	State
United States	University of Texas Southwestern	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Eliminate its growth and tumor viability.	To evaluate if SABR to small renal tumors is able to eliminate its growth and viable tumor.	2 years
Secondary	Adverse events	To describe the adverse events associated with the administration of SABR to renal tumors.	2 years
Secondary	growth rate of renal tumors	To measure the growth rate of renal tumors after SABR treatment.	2 years
Secondary	Renal function	To measure the changes in kidney function, creatinine levels, renal perfusion and GFR after SABR treatment	2 years
Secondary	Tumor Viability	To measure tumor viability pathologically one year after SABR treatment with biopsy.	one year
Secondary	progression of disease	To assess radiographic changes to the renal tumor after SABR treatment including tumor viability, enhancement necrosis,T2 tumor cellularity with diffusion-weighted imaging. To assess local, regional and systemic progression of disease after SABR to SRM .To assess time to progression (TTP) of disease from the first SABR treatment.; To assess progression free survival (PFS). PFS is defined as the length of time from start of treatment to the time of loco-regional disease progression or death from any cause.; To assess overall survival (OS). OS is defined as the duration of time from start of treatment to the time of death from any cause.; To assess tumor growth, local failure and indeterminate disease response (IDR).	2 years